A 52-week phase III RCT finds sitagliptin preserves hip bone density in women with type 2 diabetes, which declines on placebo, but with no effect at other sites. PICO summary and commentary.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
An RCT finds an interdisciplinary care model with family empowerment improves blood pressure, glucose, and psychosocial outcomes in comorbid hypertension and diabetes. PICO summary and commentary.
An RCT finds adding ezetimibe to metformin raises PPAR-gamma and adiponectin expression and improves insulin resistance in diabetic fatty liver disease, though endpoints are surrogate. PICO summary and commentary.
A phase-1 crossover study in healthy Korean volunteers found a fixed-dose enavogliflozin/gemigliptin combination pharmacokinetically equivalent to the separate tablets, with food delaying only the time to peak. PICO summary and expert commentary.
A multicentre RCT finds adding orlistat to pioglitazone and metformin improves weight, visceral fat, and insulin sensitivity in obese type 2 diabetes, but not HbA1c. PICO summary and commentary.
A small CGM crossover study finds 30 g/day defatted fenugreek flakes reduces 24-hour glucose excursions and variability in type 2 diabetes. PICO summary and commentary.
A secondary analysis finds probiotics plus omega-3 improve beta-cell function only marginally versus baseline and not versus placebo when adjusted, though secondary metabolic markers improve. PICO summary and commentary.
A single-blind RCT finds pictorial foot-care education substantially improves knowledge and practice scores in people with type 2 diabetes in Karachi slums. PICO summary and commentary.
A combined mouse and clinical study finds the anabolic agent rhPTH(1-34) reverses low bone turnover in type 2 diabetic bone disease and improves bone density more than alendronate. PICO summary and commentary.
A small mechanistic trial in youth-onset type 2 diabetes finds metformin and liraglutide shift gut bacteria and bile acids; bile-acid metabolites, not microbiota shifts, track with glucose. PICO summary and commentary.